BPC-157
bpc157-pcac-2026
The prediction
PCAC does NOT recommend Category 1 (unrestricted compounding) for BPC-157 at the 2026-07-23 meeting; outcome is Category 2 return, deferral, or partial/conditional status short of full Cat 1
Regulator agent dominates regulatory decisions. FDA default on unapproved peptides without US safety dossier = not-Cat-1. Counter-narrative ~30%: split decision or conditional Cat 1. Deep-read of OnHealthcare analysis not yet done; could shift +/-10 pts.
Trajectory
- 18 April 2026 · created70%signal strength 42
Regulator agent dominates regulatory decisions. FDA default on unapproved peptides without US safety dossier = not-Cat-1. Counter-narrative ~30%: split decision or conditional Cat 1. Deep-read of OnHealthcare analysis not yet done; could shift +/-10 pts.
- 2026-04-19 07:00 UTC · Ra run70%0· signal 42
Holding original probability but flagging in meta-cognition that this row is historical evidence of anchoring bias rather than a current view.
Counter-narrativeOriginal forecast superseded by revised multi-peptide forecast pcac-july-multi-peptide; anchoring bias noted in meta
- (no new direct evidence)
- 2026-04-22 04:04 UTC · Ra runread brief →60%-0.10· signal 48
BPC-157 nomination withdrawn from Cat 2 by nominator — 12-peptide removal wave suggests political momentum toward reclassification. RFK publicly announced ~14/19 moving to Cat 1. Hims +49% pricing in favorable outcome. Skeptic argues political fix may be in; Bayesian moved -0.10 reflecting real but not overwhelming shift. PCAC still advisory; career FDA staff may resist full Cat 1 without safety data.
Counter-narrativePCAC may grant conditional Cat 1 under political pressure from RFK despite absent safety dossier; nomination withdrawal signals process is political, not scientific
- 2026-04-22 10:52 UTC · Ra runread brief →58%-0.02· signal 48
Second-pass council (10:52 UTC, predates 15:30 run). ProPublica Las Vegas adverse event gives career scientists safety ammunition. Superseded by 15:30 run which found PCAC vacancy mechanism — a stronger structural signal.
Counter-narrativePCAC grants full Cat 1 under RFK political pressure despite absent safety dossier; ProPublica investigation may not gain traction before July
- 2026-04-22 15:30 UTC · Ra runread brief →55%-0.05· signal 50
PCAC has 6 vacancies including chair — Kennedy controls appointments. STAT reports advisers expected to support. Conditional Cat 1 pathway preserves the not-full-Cat-1 prediction even as political pressure mounts. ProPublica/Woodcock pushback is scientific, not political — and this is a political process. Modest move from 0.60 to 0.55.
Counter-narrativePCAC grants full unrestricted Cat 1 under political pressure; Kennedy fills 6 vacancies with pro-access appointees before July 23, making career-staff resistance moot
- 2026-04-23 07:04 UTC · Ra runread brief →55%0· signal 48
BPC-157 confirmed for Day 1 of July 23-24 PCAC. PCAC recommendations non-binding. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies before July 23 making full Cat 1 recommendation near-certain
- 2026-04-24 07:04 UTC · Ra runread brief →55%0· signal 48
Legal analysis confirms Cat 2 removal does not authorize compounding — PCAC deliberation and Cat 1 placement remain required steps. No vacancy appointment news. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain regardless of safety dossier quality
- 2026-04-25 07:04 UTC · Ra runread brief →55%0· signal 48
FDA Law Blog two-part analysis confirms rulemaking requirement post-PCAC recommendation. Public comment deadline July 9. 89 days to resolution. No vacancy appointments announced. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-04-26 07:04 UTC · Ra runread brief →55%0· signal 48
88 days to PCAC. Kennedy vacancy-filling authority confirmed but no specific appointments announced. Absence of appointment news is a weak signal for status quo. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-04-27 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review: 87 days to PCAC. Six vacancies confirmed, zero appointments announced. Absence of appointment news is weak accumulating signal for status quo. Public comment docket open through July 22. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- 2026-04-28 04:04 UTC · Ra runread brief →55%0· signal 48
86 days to PCAC. Zero vacancy appointments announced. Public comment deadline July 9. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-04-29 07:04 UTC · Ra runread brief →55%0· signal 48
85 days to PCAC. Zero vacancy appointments in 6 weeks since Kennedy commitment. Public comment deadline July 9. Accumulating absence weakly reinforces status quo. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- 2026-04-30 07:04 UTC · Ra runread brief →55%0· signal 48
84 days to PCAC. Zero vacancy appointments in 7 weeks since Kennedy commitment. Public comment deadline July 9. Absence of appointment news accumulates. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-01 07:04 UTC · Ra runread brief →55%0· signal 48
Kennedy filled ACIP vacancies Feb 27 confirming appointment authority but has not touched PCAC in 9 weeks. PCAC roster: 3 voting members, 1 industry liaison, no chair of 12 authorized. Absence accumulates. 83 days to PCAC. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-02 07:04 UTC · Ra runread brief →55%0· signal 48
FDA 503B GLP-1 exclusion proposal signals career staff still active on compounding oversight; tangential to PCAC but reveals institutional conservatism. 82 days to PCAC. No vacancy appointments in 10 weeks. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-03 07:04 UTC · Ra runread brief →55%0· signal 48
81 days to PCAC. Zero vacancy appointments in 10+ weeks. Partnership for Safe Medicines entered compounding discourse — pharma-backed advocacy that could give career scientists institutional backing for caution. Weak signal, not probability-moving. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-04 07:04 UTC · Ra runread brief →55%0· signal 48
PCAC formally renewed to April 2028 (Federal Register April 30). Institutional vehicle confirmed for July 2026 and Feb 2027 sessions. 11 weeks zero PCAC appointments. PREMORTEM: Kennedy batch-appoints 6 members late May; reconstituted panel votes full Cat 1 Day 1; political framing supersedes scientific. Condition partially present via ACIP Feb 27. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-05 07:04 UTC · Ra runread brief →55%0· signal 48
79 days to PCAC. Zero vacancy appointments in 11 weeks. Peptide Examiner confirms individual evaluation with conditions framework — conditional Cat 1 resolves this forecast TRUE. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-06 07:04 UTC · Ra runread brief →55%0· signal 48
78 days to PCAC. Zero vacancy appointments in 11+ weeks. Orrick May 2026 503B exclusion analysis confirms career staff institutional conservatism persists. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-07 07:04 UTC · Ra runread brief →55%0· signal 48
77 days to PCAC. Zero vacancy appointments in 12 weeks since Kennedy commitment. No material new evidence. Public comment deadline July 9. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-08 07:04 UTC · Ra runread brief →55%0· signal 48
76 days to PCAC. Correction: 4 seated members confirmed via FDA roster not 3 as prior briefs. Zero vacancy appointments in 12+ weeks. HealingMaps reports 7 peptides on July agenda broader than 4-peptide basket. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-09 07:04 UTC · Ra runread brief →55%0· signal 48
75 days to PCAC. Foley Lardner May 2026 explicitly clarifies Cat 2 removal does not authorize compounding or constitute Cat 1 status — reinforces conservative thesis. Day 1 July 23 agenda confirms BPC-157 KPV TB-500 MOTs-C placement. No vacancy fills. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees and committee grants unrestricted Cat 1 to BPC-157 despite absent US safety dossier
- 2026-05-10 07:04 UTC · Ra runread brief →55%0· signal 48
74 days to PCAC. Zero vacancy appointments in 12+ weeks. Legal consensus (Foley Orrick NLR) stable: Cat 2 removal ≠ Cat 1 authorization. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees making full Cat 1 near-certain
- 2026-05-11 07:04 UTC · Ra runread brief →55%0· signal 48
73 days to PCAC. Zero vacancy appointments in 12+ weeks. Legal consensus (Foley Frier Levitt) stable: Cat 2 removal ≠ Cat 1 authorization. Premortem this week targeted hims-peptide-launch. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- 2026-05-12 07:04 UTC · Ra runread brief →55%0· signal 48
72 days to PCAC. Zero vacancy appointments in 13+ weeks. Hims earnings call referenced July PCAC as regulatory clarity trigger confirming market weight on this event. No material new evidence. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-13 07:04 UTC · Ra runread brief →55%0· signal 48
71 days to PCAC. Meeting now confirmed as two-day session (July 23-24) covering 7 peptides. Expanded agenda does not directionally change BPC-157 outlook. Zero vacancy appointments in 14+ weeks. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-14 07:04 UTC · Ra runread brief →55%0· signal 48
70 days to PCAC. Zero vacancy appointments in 14+ weeks. No new evidence. Two-day 7-peptide agenda carries forward. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-15 07:04 UTC · Ra runread brief →55%0· signal 48
69 days to PCAC. Public comment period confirmed (July 9 deadline for advance distribution to committee). Zero vacancy appointments in 15+ weeks. Procedural not directional. Holding.
Counter-narrativeKennedy fills all 6 PCAC vacancies with pro-access appointees before July 23 making full Cat 1 near-certain
- 2026-05-16 07:04 UTC · Ra runread brief →55%0· signal 48
68 days to PCAC. Federal Register confirms July 23-24 agenda and July 9 advance-distribution deadline for public comments. Zero new committee appointments in 16+ weeks. Substack narrative pressure without procedural news. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://thepeptidelist.substack.com/p/kennedys-fda-just-brought-bpc-157
- 2026-05-17 07:04 UTC · Ra runread brief →55%0· signal 42
67 days to PCAC. ProPublica adds institutional safety counter-pressure but is priced into existing 15-25% Cat-1 reference class. No new committee appointments. Holding.
Counter-narrativeProPublica institutional pre-meeting pressure already inside the not-Cat-1 base rate; falsifier (3+ RFK-aligned PCAC appointments before July 9) shows zero progress in 17 weeks
- 2026-05-18 07:04 UTC · Ra runread brief →55%0· signal 42
66 days to PCAC. NatLawReview legal analysis confirms Cat 2 removal does not automatically confer Cat 1 — individual PCAC vote required per peptide with safety-dossier review. Zero vacancy appointments in 17+ weeks. No new directional evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain
- 2026-05-19 07:04 UTC · Ra runread brief →55%0· signal 42
65 days to PCAC. Foley & Lardner third AmLaw 100 firm publishing client advisory. Legal infrastructure non-directional. Zero vacancy appointments in 18+ weeks. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain
- 2026-05-20 07:04 UTC · Ra runread brief →55%0· signal 48
64 days to PCAC. Zero vacancy appointments in 18+ weeks. Roster: 4 seated members of 12 authorized, no chair. Legal consensus stable (Foley Orrick NLR): Cat 2 removal ≠ Cat 1. No material new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-05-21 07:04 UTC · Ra runread brief →55%0· signal 48
63 days to PCAC. Quorum risk surfaced: NatLawReview flags committee does not appear to have quorum with 4 of 12 seats filled no chair. Dual-direction signal: no quorum = no Cat 1 recommendation (resolves TRUE); Kennedy batch-fills = pro-access majority (resolves FALSE). Wash at current probability. Zero vacancy appointments in 19+ weeks. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-05-22 07:04 UTC · Ra runread brief →55%0· signal 48
62 days to PCAC. Zero vacancy appointments in 19+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no Cat 1 recommendation (TRUE); batch-fill = pro-access majority (FALSE). TRIUMPH-1 readout creates fresh GLP-1 media cycle but no direct PCAC impact. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- 2026-05-23 07:04 UTC · Ra runread brief →55%0· signal 48
61 days to PCAC. Zero vacancy appointments in 19+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no recommendation (TRUE); batch-fill = pro-access majority (FALSE). ACIP Feb 27 appointments prove capacity but PCAC remains untouched. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- 2026-05-24 07:04 UTC · Ra runread brief →55%0· signal 48
60 days to PCAC. Zero vacancy appointments in 20+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no recommendation (TRUE); batch-fill = pro-access majority (FALSE). Batch appointment pattern (ACIP Feb 27) could repeat at T-30. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-05-26 07:04 UTC · Ra runread brief →55%0· signal 48
58 days to PCAC. Zero vacancy appointments in 20+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no recommendation (TRUE); batch-fill = pro-access majority (FALSE). ACIP Feb 27 batch-appointment pattern is reference class for T-30 burst. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/30/2026-08378/advisory-committee-pharmacy-compounding-advisory-committee-renewal
- 2026-05-27 07:04 UTC · Ra runread brief →55%0· signal 48
57 days to PCAC. Zero vacancy appointments in 21+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no recommendation (TRUE); batch-fill = pro-access majority (FALSE). No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/30/2026-08378/advisory-committee-pharmacy-compounding-advisory-committee-renewal
- 2026-05-28 07:04 UTC · Ra runread brief →55%0· signal 48
56 days to PCAC. Zero vacancy appointments in 22+ weeks. Quorum risk (4 of 12 seated, no chair) remains dual-direction: no quorum = no recommendation (TRUE); batch-fill = pro-access majority (FALSE). ACIP batch-appointment reference class suggests window opens ~June 23. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- 2026-05-29 07:04 UTC · Ra runread brief →55%0· signal 48
55 days to PCAC. Zero vacancy appointments in 22+ weeks. Roster: 3 voting members (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. USADA BPC-157 prohibition normalizes substance as real drug — cuts both ways for Cat 1. No new directional evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with pro-access appointees before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- 2026-05-30 07:04 UTC · Ra runread brief →55%0· signal 48
54 days to PCAC. ACIP FACA ruling (March 2026 court stay) missed by prior Ra runs — constrains unqualified batch-fill but not qualified appointments. 23 weeks zero PCAC appointments. Multiple committee renewals in Federal Register May 26-29 show FDA admin machinery functioning normally. Quorum risk persists.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 — FACA expertise requirement satisfied — making Cat 1 conferral near-certain
- https://www.apha.org/news-and-media/news-releases/apha-news-releases/federal-judge-blocks-immunization-schedule-changes
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/05/29/2026-10674/advisory-committee-psychopharmacologic-drugs-advisory-committee-renewal
- 2026-05-31 07:04 UTC · Ra runread brief →55%0· signal 48
53 days to PCAC. Zero vacancy appointments in 23+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. ACIP FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 30 days. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-06-01 07:04 UTC · Ra runread brief →55%0· signal 48
52 days to PCAC. Zero vacancy appointments in 23+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. ACIP FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 29 days. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-06-02 07:04 UTC · Ra runread brief →55%0· signal 48
51 days to PCAC. Zero vacancy appointments in 24+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 28 days. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fagron.us/newsroom/pharmacy-compounding-advisory-committee-pcac
- 2026-06-03 07:04 UTC · Ra runread brief →55%0· signal 48
50 days to PCAC. Zero vacancy appointments in 24+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 27 days. ADA conference June 5-8 absorbs media oxygen. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://peptidewiki.co/blog/fda-7-peptides-july-2026-reclassification
- 2026-06-04 07:04 UTC · Ra runread brief →55%0· signal 48
49 days to PCAC. Zero vacancy appointments in 24+ weeks. Precision Peptide Company signed 503A compounding deal for BPC-157 at 25K Rx/day capacity June 2 — commercial market pre-positioning for favorable outcome. Revealed-preference signal; does not change regulatory fundamentals. Oral presentation deadline June 30 in 26 days. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://finance.yahoo.com/sectors/healthcare/articles/precision-peptide-company-inc-signs-110000479.html
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- 2026-06-05 07:04 UTC · Ra runread brief →55%0· signal 48
48 days to PCAC. Zero vacancy appointments in 25+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 25 days. ADA absorbs pharma media oxygen reducing political pressure on appointments. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- 2026-06-06 07:04 UTC · Ra runread brief →55%0· signal 48
47 days to PCAC. Zero vacancy appointments in 25+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 24 days. ADA Day 2 absorbs pharma media oxygen. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.hcplive.com/view/ada-scientific-sessions-2026-preview-6-trials-to-know
- 2026-06-07 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review. 46 days to PCAC. Zero vacancy appointments in 25+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Precision Peptide 503A deal June 2 is commercial pre-positioning not regulatory signal. Oral presentation deadline June 30 in 23 days. ADA ended. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://finance.yahoo.com/sectors/healthcare/articles/precision-peptide-company-inc-signs-110000479.html
- 2026-06-08 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review. 45 days to PCAC. Zero vacancy appointments in 25+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. OneTwenty launching peptide DTC June 2026 with pharmacy network pre-built for favorable PCAC outcome — revealed-preference signal not regulatory. Oral presentation deadline June 30 in 22 days. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://onetwenty.com/blog/peptide-companies
- 2026-06-09 07:04 UTC · Ra runread brief →55%0· signal 48
44 days to PCAC. Zero vacancy appointments in 26+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Post-ADA media window opens — pharma press rotating to PCAC coverage. Oral presentation deadline June 30 in 21 days. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- 2026-06-10 07:04 UTC · Ra runread brief →55%0· signal 48
43 days to PCAC. Zero vacancy appointments in 26+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 20 days — next structural milestone. Post-ADA media window open; pharma press rotating to PCAC coverage. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-06-11 07:04 UTC · Ra runread brief →55%0· signal 48
42 days to PCAC. Zero vacancy appointments in 27+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. DOJ criminal enforcement against peptide distributors (Tailor Made $1.79M forfeiture, Watkins indictment 200+ patients) tangentially supports career-scientist caution but not probability-moving for this specific forecast. Oral presentation deadline June 30 in 19 days. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- 2026-06-12 07:04 UTC · Ra runread brief →55%0· signal 48
41 days to PCAC. Zero vacancy appointments in 27+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. TIKR frames Hims peptide ambitions as $20 billion bet — corporate narrative escalation not regulatory signal. Oral presentation deadline June 30 in 18 days. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.tikr.com/blog/hims-hers-stock-closes-eucalyptus-deal-with-a-20-billion-peptide-bet-on-deck-heres-what-to-expect
- 2026-06-13 07:04 UTC · Ra runread brief →55%0· signal 48
40 days to PCAC. Zero vacancy appointments in 27+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Kennedy filling CDC ACIP (5 members) and CDC vaccine panel but not PCAC — 27 weeks of inaction increasingly strong absence signal. Oral presentation deadline June 30 in 17 days. No new evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://finance.yahoo.com/news/hims-hers-weighs-legal-risks-150627273.html
- 2026-06-14 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review. PREMORTEM: Kennedy batch-fills 4+ vacancies stacked panel votes Cat 1. Latent condition (Kennedy has filled other committees) weakening as 28-week silence accumulates. 39 days to PCAC. Zero vacancy appointments in 28+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 16 days. Holding per June 30 checkpoint pre-commitment.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.nature.com/articles/d41586-026-01816-x
- 2026-06-15 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review. 38 days to PCAC. Zero vacancy appointments in 29 weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 15 days. 503B exclusion comment period closes June 29 creating regulatory-calendar collision with PCAC oral deadline. Industry attention maximally concentrated in 48-hour window. No probability-moving evidence. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s
- 2026-06-16 07:04 UTC · Ra runread brief →55%0· signal 48
37 days to PCAC. Zero vacancy appointments in 29+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 14 days. 503B comment period closes June 29 creating dual regulatory-calendar collision. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 14 days.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://www.myprofusions.com/what-the-fdas-june-29-2026-semaglutide-deadline-means-for-your-weight-loss-plan/
- 2026-06-17 07:04 UTC · Ra runread brief →55%0· signal 48
36 days to PCAC. Zero vacancy appointments in 30 weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 13 days. 503B comment period closes June 29 creating dual regulatory-calendar collision. PBS political framing noted but not probability-moving. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 13 days.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- 2026-06-18 07:04 UTC · Ra runread brief →55%0· signal 48
35 days to PCAC. Roster unchanged: 3 voting (Fensky Rebello Serumaga) 31 weeks without appointment. Bloomberg gold rush feature and Chainalysis $100M gray-market quantification create cautionary media environment but do not change PCAC structural dynamics. Oral presentation deadline June 30 in 12 days. 503B comment period closes June 29 in 11 days. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- 2026-06-19 07:04 UTC · Ra runread brief →55%0· signal 48
34 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. ECRI and ISMP joint white paper (May 2026) warns BPC-157 has 35/36 published studies in animals only with no Phase 1 human safety trials — creates institutional ammunition for deferral but does not change committee composition. Oral presentation deadline June 30 in 11 days. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- 2026-06-20 07:04 UTC · Ra runread brief →55%0· signal 48
33 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 10 days. 503B comment period closes June 29 in 9 days — dual regulatory-calendar collision will concentrate stakeholder positions. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. Holding.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- 2026-06-21 07:04 UTC · Ra runread brief →55%0· signal 48
Weekly review. 32 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 9 days. 503B comment period closes June 29 in 8 days — dual regulatory-calendar collision. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. Stoic: actionable — prepare for probability adjustment at June 30 checkpoint.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-06-22 07:04 UTC · Ra runread brief →55%0· signal 48
31 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 8 days. 503B comment period closes June 29 in 7 days creating triple regulatory-calendar collision with Bridge July 1 launch. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 8 days to checkpoint.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.myprofusions.com/what-the-fdas-june-29-2026-semaglutide-deadline-means-for-your-weight-loss-plan/
- 2026-06-23 07:04 UTC · Ra runread brief →55%0· signal 48
30 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 7 days. 503B comment period closes June 29 in 6 days — dual regulatory-calendar collision forces compounding industry to split advocacy between GLP-1 defense (existential) and peptide Cat 1 (growth). Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 7 days to checkpoint.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://peptidebond.com/blog-pcac-meeting-july-2026
- 2026-06-24 07:04 UTC · Ra runread brief →55%0· signal 48
29 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. Oral presentation deadline June 30 in 6 days. 503B comment period closes June 29 in 5 days — 72-hour regulatory collision with Bridge July 1 launch. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 6 days to checkpoint.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://newtropin.com/blog/bpc-157-tb-500-semax-and-mots-c-the-july-2026-fda-review-explained
- 2026-06-25 07:04 UTC · Ra runread brief →55%0· signal 48
28 days to PCAC. Zero vacancy appointments in 31+ weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. 5 days to June 30 checkpoint. 503B comment-period close June 29 plus PCAC oral deadline June 30 plus Bridge July 1 creates 72-hour regulatory triple collision fragmenting compounding-industry advocacy resources. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 5 days.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-26 07:04 UTC · Ra runread brief →55%0· signal 48
27 days to PCAC. Zero vacancy appointments in 31+ weeks. 4 days to June 30 checkpoint. Procedural clarification from search: favorable PCAC vote initiates formal rulemaking pipeline not immediate 503A placement. 503B comment-period close June 29 in 3 days plus oral-presentation deadline June 30 in 4 days fragmenting advocacy resources. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 4 days.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-27 07:04 UTC · Ra runread brief →55%0· signal 48
26 days to PCAC. Zero vacancy appointments in 32 weeks. Roster unchanged: 3 voting (Fensky Rebello Serumaga) + 1 industry liaison no chair of 12 authorized. 503B comment period EXTENDED 30 days to July 30 (Federal Register 2026-12937 published June 26) — defuses triple regulatory-calendar collision. Compounding industry advocacy no longer split between GLP-1 503B defense and peptide PCAC oral presentations. June 30 checkpoint in 3 days. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30. 3 days.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-06-28 07:04 UTC · Ra runread brief →55%0· signal 48
25 days to PCAC. Zero vacancy appointments in 33 weeks. ACIP legal precedent: federal judge blocked RFK ACIP replacements under FACA — dampens advisory committee stacking appetite across all federal panels. 503B extension to July 30 defuses calendar collision and concentrates compounding advocacy on PCAC oral presentations (deadline June 30 in 2 days). Forces partially cancel: ACIP precedent entrenches 3-member status quo while 503B extension marginally helps pro-Cat-1 advocacy quality. June 30 checkpoint in 2 days. Premortem: concentrated advocacy resources from 503B defusion may produce stronger-than-expected oral presentations, marginally weakening NOT-Cat-1 confidence.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.pharmexec.com/view/federal-judge-blocks-rfk-vaccine-advisory-council-appointments
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-29 07:04 UTC · Ra runread brief →50%-0.05· signal 48
Pre-commitment checkpoint triggers. June 30 vacancy deadline: zero appointments in 34 weeks confirmed. ACIP FACA ruling dampens advisory committee restructuring. 503B extension to July 30 concentrates advocacy on PCAC oral presentations deadline June 30. Small-panel uncertainty maximized. Moving to coin-flip per pre-commitment.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.pharmexec.com/view/federal-judge-blocks-rfk-vaccine-advisory-council-appointments
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-06-30 07:04 UTC · Ra runread brief →50%0· signal 48
PCAC oral presentation deadline TODAY June 30. Zero vacancy appointments in 35 weeks. ACIP FACA ruling continues dampening advisory committee restructuring. 7 peptides under review (4 Day 1 including BPC-157 plus 3 Day 2 DSIP Semax Epitalon). Filings not yet observable — secondary effects visible within 1-2 weeks through docket postings and industry press. Holding at coin-flip per pre-commitment.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://peptidehub.bio/journal/pcac-july-2026-bpc-157-tb-500-mots-c-hearing-guide
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- 2026-07-01 07:04 UTC · Ra runread brief →50%0· signal 48
Day 1 post-filing-deadline. Oral presentations filed June 30 not yet visible on FDA docket (3-7 business day lag). Zero vacancy appointments in 35 weeks. ACIP FACA ruling still dampens committee restructuring. National Law Review clarifies Cat 1 recommendation still requires notice-and-comment rulemaking (12+ months) before legal compounding authority. Filing quality is next catalyst. Holding at coin-flip.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- 2026-07-02 07:04 UTC · Ra runread brief →50%0· signal 48
Day 2 post-filing-deadline. Oral presentations filed June 30 not yet visible on FDA docket (3-7 business day posting lag). Zero vacancy appointments in 36 weeks. ACIP FACA ruling continues blocking committee restructuring. 3-member panel structurally locked. 21 days to meeting. Filing quality is next catalyst observable within days. Holding at coin-flip.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://peptidehub.bio/journal/pcac-july-2026-bpc-157-tb-500-mots-c-hearing-guide
- 2026-07-03 07:04 UTC · Ra runread brief →50%0· signal 48
Day 3 post-filing-deadline. Oral presentations filed June 30 not yet visible on FDA docket (3-7 business day posting lag July 7-10). Zero vacancy appointments in 36+ weeks. New detail: BPC-157 reviewed specifically for ulcerative colitis indication — narrow therapeutic framing could marginally favor Cat 1 if advocacy submitted strong GI data. No new safety data. 20 days to meeting. Holding at coin-flip.
Counter-narrativeKennedy fills 3+ PCAC vacancies with qualified pro-access pharmacists before July 9 making Cat 1 conferral near-certain; alternatively PCAC lacks quorum and cannot issue any recommendation
- 2026-07-04 07:04 UTC · Ra runread brief →50%0· signal 48
Day 4 post-filing-deadline. July 4 holiday no docket updates. Oral presentations expected July 7-10. Zero vacancy appointments in 37+ weeks. 19 days to meeting. Holding at coin-flip.
Counter-narrativeKennedy fills PCAC vacancies with pro-access appointees before July 9 making Cat 1 near-certain; alternatively 3-member committee votes unanimously for all four
- https://peptidehub.bio/journal/pcac-july-2026-bpc-157-tb-500-mots-c-hearing-guide
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://kineticcompounds.com/fda-pcac-to-review-peptide-compounding-what-the-july-2026-hearing-means/
- 2026-07-05 07:04 UTC · Ra runread brief →40%-0.10· signal 55
PCAC reconstituted from 3 to 14 members; AP investigation June 29 found 7/14 have peptide business ties; FDA staff briefing documents recommend against all 7 peptides citing no human clinical trials. Pro-peptide panel composition increases Cat 1 probability but FDA staff opposition anchors against. 18 days to meeting. CRITICAL: Ra missed reconstitution for 6 consecutive runs June 29-July 4.
Counter-narrative7 of 14 reconstituted members have conflict-of-interest ties but appointees may vote conservatively under media scrutiny; FDA staff recommendation against creates strong informational anchor; advisory vote is non-binding
- 2026-07-06 07:04 UTC · Ra runread brief →40%0· signal 48
Day 1 post-holiday. No docket updates. Reconstitution dynamics fully priced in July 5. Next independent variable: oral presentation filings expected on FDA docket July 7-10. Written comments deadline July 9. Public comment close July 22. Premortem target this week. 17 days to meeting. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel votes as bloc on filing-quality strength; oral presentations filed June 30 contain compelling Croatian GI safety data; UC indication framing narrows safety case
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://abcnews.com/Health/wireStory/fda-panel-peptides-include-experts-promote-unproven-chemicals-134321957
- https://thepeptideexaminer.com/news/fda-advisory-committee-july-2026-preview
- 2026-07-07 07:04 UTC · Ra run· flaggedread brief →35%-0.15· signal 65
FDA named 8 new PCAC panelists June 29 filling 11 of 12 seats; majority involved with businesses promoting or prescribing peptides including Bobby Harshbarger (pharmacist TN state senator whose mother Rep Diana Harshbarger lobbied FDA on peptide access); STAT reports conflicts of interest; weighted posterior 0.35 NOT Cat 1 (0.35-0.40 if appointments hold × 80-85% + 0.50 if FACA blocked × 15-20%)
Counter-narrativeFACA challenge risk ~15-20% per ACIP precedent could block appointments; BPC-157 safety case weakest of seven peptides with 35/36 studies animal-only per ECRI/ISMP — pro-access panel may still defer on safety grounds
- 2026-07-08 07:04 UTC · Ra runread brief →35%0· signal 65
No FACA challenge at T-15 days; FACA probability decaying from ~15-20% to ~10% — posterior impact ~0.02 insufficient for formal update; PCAC meeting confirmed July 23-24 White Oak; Day 1 BPC-157 KPV TB-500 MOTS-C Day 2 DSIP Semax Epitalon; formal rulemaking post-vote means earliest pharmacy availability Q1 2027; holding 0.35
Counter-narrativeNo FACA challenge filed at T-15 days reduces challenge probability from ~15-20% to ~10%; BPC-157 safety case remains weakest of seven peptides with 35/36 studies animal-only — pro-access panel may still defer on safety grounds
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.affinitywholehealth.com/blog/upcoming-pcac-meeting-what-the-july-2026-review-means-for-compounded-peptides
- https://peptidehub.bio/journal/pcac-july-2026-bpc-157-tb-500-mots-c-hearing-guide
- 2026-07-10 07:04 UTC · Ra runread brief →35%0· signal 48
Written comments deadline passed July 9 — panelists briefing material sealed. No FACA challenge at T-13; probability decaying toward 5%. FDA staff recommendation against remains strongest anchor. BPC-157 weakest safety case 35/36 studies animal-only. 13 days to resolution. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel votes as bloc; oral presentations filed June 30 contain compelling GI safety data; UC indication framing narrows safety case
- 2026-07-11 07:04 UTC · Ra runread brief →35%0· signal 48
Day 1 post-comment-lock. Oral presentation filings still not on FDA docket at 8 business days — outer edge of normal 3-7d posting lag. No FACA challenge at T-12 days; probability fading toward ~5%. FDA staff recommendation against remains strongest anchor. 12 days to meeting. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel votes as bloc; oral presentations filed June 30 contain compelling GI safety data; UC indication framing narrows safety case
- 2026-07-12 07:04 UTC · Ra runread brief →35%0· signal 48
T-11 days. Briefing docs expected publicly within 1-3 days (7-10 day pre-meeting posting window). Oral presentations still not on public docket at 9 business days. No FACA challenge. FDA staff recommendation against remains strongest anchor. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel votes as bloc; oral presentations filed June 30 contain compelling GI safety data; UC indication framing narrows safety case
- 2026-07-13 07:04 UTC · Ra runread brief →35%0· signal 48
FDA posted all 7 briefing docs; staff recommends against all seven citing not-well-characterized insufficient-human-safety-data unassessed-immunogenicity-risk. BPC-157 35/36 animal-only. Confirms known stance; panel composition remains key variable. T-10 days. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel votes as bloc overriding FDA staff; oral presentations contain compelling GI safety data under UC indication framing
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://peptidedossier.com/guides/pcac-hearing-bpc-157-tb-500/
- 2026-07-14 07:04 UTC · Ra runread brief →35%0· signal 48
T-9 days. No new material since briefing doc publication. Staff against all 7 confirmed. Panel composition dominant variable. 503B comment period closes July 30 creating regulatory convergence week July 23-30. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; oral presentations contain compelling GI safety data under UC indication framing
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://peptidedossier.com/guides/pcac-hearing-bpc-157-tb-500/
- 2026-07-15 07:04 UTC · Ra runread brief →35%0· signal 48
T-8 days. Partnership for Safe Medicines formally submitted PCAC comments urging rejection of all 7 peptides citing Chinese API sterility violations and unassessed immunogenicity. Expected pharma-industry opposition aligned with FDA staff — no new information. Panel composition remains dominant variable. No oral presentations on public docket. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; oral presentations contain compelling GI safety data under UC indication framing
- 2026-07-16 07:04 UTC · Ra runread brief →35%0· signal 48
T-7 days. BofA Lutz raised HIMS PT $25 to $36 Neutral maintained noting FDA staff recommendation against tempers peptide optionality. Hims launched consumer peptide education campaign on Instagram. No new regulatory evidence. Oral presentations still absent from public docket. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; Hims consumer pre-positioning validates industry confidence in Cat 1 outcome
- https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60225352/hims-hers-healths-peptide-opportunity-tempered-by-fda-recommendation-says-analyst
- https://stocktwits.com/news-articles/markets/equity/hims-peptides-campaign-key-fda-meeting/cZmzKDjR7oN
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-17 07:04 UTC · Ra runread brief →35%0· signal 48
T-6. No new regulatory evidence. Oral presentations absent from FDA public docket at 12+ business days past filing well beyond 3-7 day norm. PSM opposition locked in. Public comment closes July 22. Panel composition remains dominant variable. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; oral presentations filed June 30 contain compelling GI safety data under UC indication framing
- 2026-07-18 07:04 UTC · Ra runread brief →35%0· signal 48
T-5. No new regulatory evidence. Quantified 2024 PCAC reference class: 11 Yes vs 167 No across 13 substances CJC-1295 0-13-0 Ipamorelin 0-12-1 Thymosin Alpha-1 4-17-0. Present panel reconstituted under Kennedy — independent variable changed. BPC-157 weakest of 4 Day 1 candidates fewer than 36 human subjects. Oral presentations absent from FDA docket at 13+ business days. Public comment closes July 22. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; oral presentations filed June 30 contain compelling GI safety data under UC indication framing
- 2026-07-19 07:04 UTC · Ra runread brief →35%0· signal 48
T-4 days. No new regulatory evidence. Oral presentations still absent from FDA docket. PSM opposition filed. Public comment period closed July 22. Panel composition remains dominant variable. Premortem this week: absent oral presentations as negative procedural signal. Holding.
Counter-narrativeKennedy-appointed pro-peptide panel overrides FDA staff on BPC-157; oral presentations absent from docket at 14+ business days may indicate weaker-than-assumed lobby preparation
- 2026-07-20 07:04 UTC · Ra run· flaggedread brief →72%+0.37· signal 55
T-3. MATERIAL REVERSAL. FDA background review materials now public: staff proposes ALL 7 peptides NOT added to 503A list; BPC-157 studies small/uncontrolled/contradictory. Standing 0.35 rested on pro-peptide panel plus compelling advocate oral presentations overriding staff — presentations still absent from docket, roster search surfaced standard members (Fensky/Rebello/Serumaga) not confirmable pro-peptide stacking. Reverting toward base-rate-respecting original 0.70, nudged to 0.72 on net-more-negative evidence. Flagged for operator.
Counter-narrativeKennedy/Makary FDA political pressure for peptide access could still drive the committee to override its own staff and grant Cat 1 despite the negative review
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- 2026-07-21 07:04 UTC · Ra runread brief →70%-0.02· signal 55
T-2. Panel-conflict now CONFIRMED by named outlets (PBS, NPR, US News, medicalxpress): reconstituted PCAC includes members who run peptide clinics / sell / promote peptides. Yesterday reverted to 0.72 partly on an unconfirmable pro-peptide stack; that pillar is now confirmed present, fattening the override tail. Staff-against-all-7 + advisory-follows-staff base rate (~75-80%) + oral advocate presentations still absent from docket + FAERS-documented BPC-157 hospitalization keep NOT-Cat-1 dominant, but nudge off 0.72 to base-rate-original 0.70. Not re-flagged (small delta); still flagged for operator resolution before Wed vote.
Counter-narrativeA panel reconstituted with peptide-clinic operators and peptide sellers is engineered to override a staff rejection, and a Cat 1 vote for BPC-157 is exactly what such a stack exists to produce
- https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr
- https://www.npr.org/2026/06/30/nx-s1-5876301/peptides-fda-panel-compounding-rfk
- https://www.usnews.com/news/health-news/articles/2026-07-01/fda-scientists-warn-against-expanded-peptide-access-as-kennedy-reshapes-advisory-panel
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-22 07:04 UTC · Ra runread brief →70%0· signal 56
T-1. Agenda re-confirmed: BPC-157 + KPV voted Day 1 (July 23) with all four Day-1 peptides on schedule, so the resolution basket is clean. No new regulatory evidence overnight (firehose 0 matches). Forbes July 21 skeptical science-vs-hype piece reinforces establishment-safety framing; staff-against-all-7 + advisory-follows-staff base rate + engineered-override panel net to the honest 0.70. Holding; flagged for operator resolution after Wed vote.
Counter-narrativeThe panel was deliberately reconstituted with peptide-clinic operators and sellers precisely to override the staff rejection, and a BPC-157 Cat 1 vote is the engineered outcome such a stack exists to produce.
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.peptideknow.com/blog/fda-pcac-july-2026-bpc-157-tb-500-mots-c-semax-epitalon
- https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/
- 2026-07-23 04:05 UTC · Ra runread brief →73%+0.03· signal 57
T-0, resolves TODAY (Thu Jul 23, Day 1 vote; prior briefs misdated this as Wednesday). Material clarification: after conflict-of-interest criticism FDA added 8 temporary voters (Durham/Iadecola/Lee/Mailman/Sandbrink/Skelsey/Zacharoff/Zamboni) whom ex-FDA official Peter Lurie called 'considerably more qualified and less conflicted' — diluting the stacked-panel override tail the log carried Jul 21-22. All 7 already off Cat 2 (Apr 23), so a No re-bans nothing. Nudge 0.70->0.73 toward staff-follows base case. Flagged for operator resolution after tonight's vote.
Counter-narrativeA panel still containing peptide-clinic operators could override staff and grant BPC-157 Cat 1 despite the added experts.
- https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism
- https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-24 04:04 UTC · Ra run· flaggedread brief →5%-0.68· signal 95
RESOLVES FALSE. PCAC voted 8-6-1 to recommend adding BPC-157 (ulcerative colitis) to the 503A Bulks List, overriding FDA staff who opposed all 7 -- the engineered-override tail the log discounted Jul 21-23 is exactly what happened. Original 0.70 NOT-Cat-1 -> Brier 0.49. Flagged for operator resolution as FALSE.
Counter-narrativeThe vote is advisory and non-binding so a future FDA rulemaking could still decline placement, but the forecast resolves on the PCAC recommendation, which was affirmative.
- https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
- https://time.com/article/2026/07/23/fda-committee-peptides/
- https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-25 04:04 UTC · Ra runread brief →5%0· signal 95
AWAITING OPERATOR RESOLUTION AS FALSE (2d overdue, resolution_date 2026-07-23). Post-vote confirmation across RAPS/PharmExec/PeptidesInsider that all four Day-1 peptides cleared (BPC-157/KPV/TB-500 8-6-1, MOTs-C 7-5-2) further cements the affirmative outcome the forecast bet against. Holding floor 0.05; original 0.70 NOT-Cat-1 -> Brier 0.49.
Counter-narrativeThe vote is advisory and non-binding and Cat 1 placement still needs 8-12mo notice-and-comment rulemaking that could decline it, but the forecast resolves on the PCAC recommendation, which was affirmative.
- https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
- https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
- https://peptidesinsider.com/blog/fda-peptide-panel-vote-bpc-157-kpv-2026
- https://finance.yahoo.com/healthcare/articles/precision-peptide-company-applauds-fda-110000220.html
- 2026-07-26 04:04 UTC · Ra runread brief →5%0· signal 95
OVERDUE 3 days. All four Day-1 peptides cleared (BPC-157/KPV/TB-500 8-6-1, MOTs-C 7-5-2); resolves FALSE, Brier 0.49 on original 0.70. Awaiting operator write to resolutions.tsv.
Counter-narrativeFDA could still reject the non-binding recommendation in rulemaking, but that would not undo the panel Cat-1 vote that already falsified this forecast.
- 26 Jul 2026 · resolved falseFinal Brier0.490Lead time0 days
Resolved FALSE. On 2026-07-23 the PCAC voted 8 to 6 with 1 abstention to RECOMMEND BPC-157 for addition to the 503A bulks list, i.e. the Cat-1-equivalent outcome the forecast said would not happen. KPV and TB-500 carried the same 8-6-1 tally and MOTS-c passed 7-5-2, so all four nominated peptides were recommended. Ground truth verified against bestpeptideforthat/src/data/peptides.ts pcacVote fields, which were primary-sourced at publication. THE LESSON, and it is the expensive one: the forecast reasoned that 'Regulator agent dominates regulatory decisions' and that FDA default on unapproved peptides without a US safety dossier is not-Cat-1. FDA staff DID oppose all seven substances. But the PCAC is an ADVISORY COMMITTEE, not the regulator, and it overrode its own staff. The model conflated the advisory body with the decision-maker. Future regulatory forecasts must model the advisory vote and the agency decision as TWO separate events with different actors and different base rates. The binding FDA decision is still pending and is a separate, unforecast question worth opening.
Sources at creation
- https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://www.onhealthcare.tech/p/the-category-2-peptide-unwind-how
- https://djholtlaw.com/regulatory-alert-the-legal-status-of-bpc-157-in-compounding-and-clinical-practice/
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.